Compare Heron Therapeutics Inc (HRTX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.42. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VWO | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | — |
52-Week High | $1.49 | $61.24 |
52-Week Low | $0.32 | $51.20 |
Enterprise Value | $168.21M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
VWO trades at $60.42, up 0.15% today, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with Barry Investment Advisors increasing holdings by 6.1% (SEC filing, August 10, 2026). RSI levels indicate mild overbought conditions, while support sits near $60.
Outlook remains positive due to record capital inflows into emerging markets and low 0.06% expense ratio. Risks include concentrated exposure to developing economies and China's economic volatility. The dividend yield of 2.4% offers income appeal amid global diversification trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
